EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study

Paolo Antonio Muraro, Antonio Zito, Alessio Signori, Maria Pia Sormani iD, Eleonora Rigoni, Federica Pollidoro, Roberto Bergamaschi, Alice Mariottini iD, Omar Malik, Ashwini Nandoskar, Victoria Singh-Curry, Varun Mehra und 5 weitere

Annals of Neurology · 2025-08 · 98 (2) · 294-307

DOI: 10.1002/ana.27247 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Neurology, online erschienen am 19.04.2025. Verfasst von Paolo Antonio Muraro und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Alemtuzumab, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare clinical and radiological outcomes among relapsing multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT), alemtuzumab (ATZ), and ocrelizumab (OCR).

Methods

From a London (UK) hospital‐based observational cohort, modeled data were obtained from 621 relapsing–remitting multiple sclerosis patients, who were treated with AHSCT (n = 103), ATZ (n = 204), and OCR (n = 314), and were followed up for 43, 43, and 32 median months, respectively. The annualized relapse rate, new magnetic resonance imaging (MRI) lesions, and disability progression on Expanded Disability Status Scale were assessed.

Results

AHSCT showed superior efficacy compared with ATZ and OCR. After 5‐year follow up, the mean annualized relapse rate (0.026 vs 0.087; p < 0.001), the risk of relapses (HR 0.29, 95% CI 0.13–0.63; p = 0.002), and of MRI activity (HR 0.33, 95% CI 0.15–0.72; p = 0.006) were significantly lower in AHSCT versus ATZ group. Compared with OCR, after 3‐year follow‐up AHSCT showed a significantly lower annualized relapse rate (0.028 vs 0.073; p = 0.02) and a trend to reduced risk of relapse (HR 0.45, 95% CI 0.18–1.14; p = 0.09), but similar low rates (6%) of new MRI activity (HR 0.86, 95% CI 0.28–2.67; p = 0.80). In addition, there was a similar risk of Expanded Disability Status Scale progression in AHSCT, and both ATZ (HR 1.19, 95% CI 0.71–2.00; p = 0.50) and OCR (HR 1.08, 95% CI 0.57–2.04; p = 0.82) groups.

Interpretation

AHSCT was followed by greater prevention of relapses compared with ATZ and OCR, and suppressed more profoundly MRI activity than ATZ, but similarly to OCR, albeit with shorter follow up. The risk of accumulating disability was similar among the treated groups. Studies with larger sample sizes and longer follow up may enable confirmation of these findings or detection of any additional differential effects. ANN NEUROL 2025;98:294–307

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingAlemtuzumabHematopoietic Stem Cell TransplantationAntibodies, Monoclonal, HumanizedImmunologic FactorsHumansFemaleMaleAdultTreatment OutcomeMiddle AgedCohort StudiesMagnetic Resonance ImagingTransplantation, AutologousFollow-Up StudiesYoung Adult

Substanzen

AlemtuzumabAntibodies, Monoclonal, HumanizedocrelizumabImmunologic Factors

Autor:innen und Institutionen

  • Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Imperial College Healthcare NHS Trust, London, UK.
  • Multiple Sclerosis Center, IRCCS Mondino Foundation, Pavia, Italy.
  • Department of Health Sciences, University of Genoa, Genoa, Italy.
  • Scientific Institute for research, hospitalisation, and Healthcare, University hospital San Martino, Genoa, Italy.
  • Department of Neurosciences, University of Florence, Careggi Hospital, Florence, Italy.

ORCID-Profile: Maria Pia Sormani, Alice Mariottini, Richard Nicholas, Antonio Scalfari

Zitieren

APA

Muraro, P. A., Zito, A., Signori, A., Sormani, M. P., Rigoni, E., Pollidoro, F., Bergamaschi, R., Mariottini, A., Malik, O., Nandoskar, A., Singh-Curry, V., Mehra, V., Kazmi, M., Gabriel, I., Silber, E., Nicholas, R., & Scalfari, A. (2025). Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study. Annals of Neurology, 98(2), 294-307. https://doi.org/10.1002/ana.27247

Vancouver

Muraro PA, Zito A, Signori A, Sormani MP, Rigoni E, Pollidoro F, et al. Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study. Annals of Neurology. 2025;98(2):294-307. doi:10.1002/ana.27247

BibTeX
@article{Muraro2025,
  author = {Muraro, Paolo Antonio and Zito, Antonio and Signori, Alessio and Sormani, Maria Pia and Rigoni, Eleonora and Pollidoro, Federica and Bergamaschi, Roberto and Mariottini, Alice and Malik, Omar and Nandoskar, Ashwini and Singh-Curry, Victoria and Mehra, Varun and Kazmi, Majid and Gabriel, Ian and Silber, Eli and Nicholas, Richard and Scalfari, Antonio},
  title = {Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study},
  journal = {Annals of Neurology},
  year = {2025},
  volume = {98},
  number = {2},
  pages = {294--307},
  doi = {10.1002/ana.27247}
}
Kostenlos starten →